Publications by authors named "B Gertz"
Inclusive research combines the expertise of academically trained researchers with the lived experience of individuals with disabilities to render results that are more accessible, accountable, and meaningful to the disability community. In this case study, adults with intellectual and developmental disabilities (IDD) contributed as co-researchers to a series of studies on mental health of adults with intellectual disability. The research model, specific engagement strategies, and lessons learned are shared.
View Article and Find Full Text PDFBackground: Tourette syndrome (TS) is a neurodevelopmental disorder characterized by motor and phonic tics.
Objective: To assess the safety and efficacy of deutetrabenazine (Teva Neuroscience, Inc, Parsippany, NJ), a vesicular monoamine transporter 2 inhibitor, in children and adolescents with TS.
Methods: Alternatives for Reducing Tics in TS (ARTISTS) open-label extension (OLE) (NCT03567291) was a 54-week, global, phase 3, open-label extension study of deutetrabenazine (6-48 mg daily) conducted May 28, 2018 to April 3, 2020 with a 2-week randomized withdrawal period.
Article Synopsis
- Tourette syndrome is a neurodevelopmental disorder that leads to the development of motor and phonic tics, and this study focuses on testing deutetrabenazine, a drug previously approved for other conditions, to see if it can help manage these tics.
- The ARTISTS 2 study recruited children and adolescents aged 6 to 16 with Tourette syndrome, with participants randomly assigned to receive either low-dose, high-dose deutetrabenazine, or a placebo over an 8-week period.
- The main measure of effectiveness was the change in tic severity, assessed using the Yale Global Tic Severity Scale, while safety was evaluated through monitoring side effects and other health metrics.
Importance: Tourette syndrome is a neurodevelopmental disorder characterized by childhood onset of motor and phonic tics; treatments for tics are associated with safety concerns. Deutetrabenazine is a selective vesicular monoamine transporter 2 inhibitor approved for the treatment of chorea associated with Huntington disease and tardive dyskinesia in adults.
Objective: To examine whether deutetrabenazine is effective and safe for the treatment of Tourette syndrome in children and adolescents.